Add BrightSurf on Google Email

Scientists uncover that albumin is prevented from crossing the placenta – open opportunities for design of long-acting biologic medicines with limited fetal exposure

Researchers uncover the placenta distinguishes between antibodies and albumin, allowing for the design of long-acting biologic medicines with reduced fetal exposure. Fusion of IgG antibodies to albumin inhibits transport across the placenta, enabling the development of safer treatments during pregnancy.

Hitting HIT: Heparin therapy

Researchers at LMU have discovered that inhibition of a specific enzyme can effectively prevent heparin-induced thrombocytopenia (HIT), a potentially life-threatening condition. The study shows that Btk inhibitors can block platelet activation and prevent the formation of harmful clots, offering a new promising therapeutic option for t...

SourceLudwig-Maximilians-Universität München·JournalBlood Advances·DateDec 20, 2019

It's Fab! A hidden touch of antibody

Antibodies recognize viruses and cancer cells via Fab arms, but now researchers know the Fab portion also directly binds to Fc receptors. This discovery opens up a new strategy for developing therapeutic antibodies with enhanced binding properties.

SourceNagoya City University·JournalScientific Reports·DateAug 21, 2019